Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Atorvastatin May Mitigate Risk of Cardiac Events Due to Anthracycline Use in Lymphoma
August 10th 2023Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.
Read More
Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.
Read More
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Patients With CML Feel Shared Decision-Making Is Lacking, Want More Focus on QOL
July 25th 2023Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
Higher Spleen Volume at HSCT Associated With Worse Outcomes in AML
July 21st 2023A recent study found that higher spleen volume before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was associated with worse overall survival and higher nonrelapse mortality incidence in patients with acute myeloid leukemia (AML).
Read More
Dr Wojciech Jurczak Discusses Changing Treatment Options for R/R DLBCL
July 20th 2023Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Read More
Common CVD Biomarkers May Hold Prognostic Value in MDS, Study Finds
July 19th 2023The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.
Read More
ePROM Monitoring of Patients With Inflammatory Arthritides May Be Beneficial, Review Suggests
July 15th 2023Utilizing electronic patient-reported outcome measures (ePROMs) may hold potential to reduce health care resource utilization without affecting outcomes for patients with inflammatory arthritides, such as rheumatoid arthritis.
Read More
Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
July 14th 2023The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
Read More
Dr Fabian Lang on the Importance of Patient Involvement in CML Treatment Decisions
July 7th 2023In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
Race-Neutral Testing Could Reduce Bias in Lung Transplant Allocation, Study Suggests
June 29th 2023Interpreting spirometry with race-specific reference equations led to a lower Lung Allocation Score (LAS) for Black patients and higher LAS among White patients, which could potentially contribute to racially biased allocation of lung transplants.
Read More
Earlier Use of CAR T Cells Holds Promise in Blood Cancers, but Access Remains an Issue
June 23rd 2023A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.
Read More
ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening
June 22nd 2023A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.
Read More
FDA Approves Talazoparib Plus Enzalutamide for mCRPC With HRR Gene Mutations
June 21st 2023Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations in the phase 3 TALAPRO-2 trial.
Read More
Timely Initiation of Targeted Therapy for NSCLC Improves Outcomes, Study Finds
June 20th 2023Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.
Read More
IMRT for Prostate Cancer Not Associated With Increased Risk of Second Primary Cancers, Study Finds
June 16th 2023There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.
Read More
Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC
June 15th 2023A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.
Read More
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
June 9th 2023Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
Read More
Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting
June 9th 2023An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.
Read More